Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.

Ott PA, Pavlick AC, Johnson DB, Hart LL, Infante JR, Luke JJ, Lutzky J, Rothschild NE, Spitler LE, Cowey CL, Alizadeh AR, Salama AK, He Y, Hawthorne TR, Bagley RG, Zhang J, Turner CD, Hamid O.

Cancer. 2019 Apr 1;125(7):1113-1123. doi: 10.1002/cncr.31892. Epub 2019 Jan 28.

PMID:
30690710
2.

An extreme magneto-ionic environment associated with the fast radio burst source FRB 121102.

Michilli D, Seymour A, Hessels JWT, Spitler LG, Gajjar V, Archibald AM, Bower GC, Chatterjee S, Cordes JM, Gourdji K, Heald GH, Kaspi VM, Law CJ, Sobey C, Adams EAK, Bassa CG, Bogdanov S, Brinkman C, Demorest P, Fernandez F, Hellbourg G, Lazio TJW, Lynch RS, Maddox N, Marcote B, McLaughlin MA, Paragi Z, Ransom SM, Scholz P, Siemion APV, Tendulkar SP, Van Rooy P, Wharton RS, Whitlow D.

Nature. 2018 Jan 10;553(7687):182-185. doi: 10.1038/nature25149.

PMID:
29323297
3.

A massive, quiescent galaxy at a redshift of 3.717.

Glazebrook K, Schreiber C, Labbé I, Nanayakkara T, Kacprzak GG, Oesch PA, Papovich C, Spitler LR, Straatman CM, Tran KH, Yuan T.

Nature. 2017 Apr 5;544(7648):71-74. doi: 10.1038/nature21680.

PMID:
28382981
4.

A direct localization of a fast radio burst and its host.

Chatterjee S, Law CJ, Wharton RS, Burke-Spolaor S, Hessels JW, Bower GC, Cordes JM, Tendulkar SP, Bassa CG, Demorest P, Butler BJ, Seymour A, Scholz P, Abruzzo MW, Bogdanov S, Kaspi VM, Keimpema A, Lazio TJ, Marcote B, McLaughlin MA, Paragi Z, Ransom SM, Rupen M, Spitler LG, van Langevelde HJ.

Nature. 2017 Jan 4;541(7635):58-61. doi: 10.1038/nature20797.

PMID:
28054614
5.

GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses.

Kwek SS, Kahn J, Greaney SK, Lewis J, Cha E, Zhang L, Weber RW, Leonard L, Markovic SN, Fong L, Spitler LE.

Oncoimmunology. 2015 Oct 29;5(4):e1101204. eCollection 2016 Apr.

6.

A repeating fast radio burst.

Spitler LG, Scholz P, Hessels JW, Bogdanov S, Brazier A, Camilo F, Chatterjee S, Cordes JM, Crawford F, Deneva J, Ferdman RD, Freire PC, Kaspi VM, Lazarus P, Lynch R, Madsen EC, McLaughlin MA, Patel C, Ransom SM, Seymour A, Stairs IH, Stappers BW, van Leeuwen J, Zhu WW.

Nature. 2016 Mar 10;531(7593):202-5. doi: 10.1038/nature17168. Epub 2016 Mar 2.

PMID:
26934226
7.

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS.

J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.

PMID:
26014293
8.

Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma.

Spitler LE, Boasberg P, O'Day S, Hamid O, Cruickshank S, Mesko S, Weber RW.

Am J Clin Oncol. 2015 Feb;38(1):61-7. doi: 10.1097/COC.0b013e318287bbae.

PMID:
25616203
9.

Biological Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated With GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma.

Spitler LE, Cao H, Piironen T, Whiteside TL, Weber RW, Cruickshank S.

Am J Clin Oncol. 2017 Apr;40(2):207-213. doi: 10.1097/COC.0000000000000124.

10.

A supermassive black hole in an ultra-compact dwarf galaxy.

Seth AC, van den Bosch R, Mieske S, Baumgardt H, den Brok M, Strader J, Neumayer N, Chilingarian I, Hilker M, McDermid R, Spitler L, Brodie J, Frank MJ, Walsh JL.

Nature. 2014 Sep 18;513(7518):398-400. doi: 10.1038/nature13762.

PMID:
25230660
11.

A strong magnetic field around the supermassive black hole at the centre of the Galaxy.

Eatough RP, Falcke H, Karuppusamy R, Lee KJ, Champion DJ, Keane EF, Desvignes G, Schnitzeler DH, Spitler LG, Kramer M, Klein B, Bassa C, Bower GC, Brunthaler A, Cognard I, Deller AT, Demorest PB, Freire PC, Kraus A, Lyne AG, Noutsos A, Stappers B, Wex N.

Nature. 2013 Sep 19;501(7467):391-4. doi: 10.1038/nature12499. Epub 2013 Aug 14.

PMID:
23945588
12.

Transformation of a star into a planet in a millisecond pulsar binary.

Bailes M, Bates SD, Bhalerao V, Bhat ND, Burgay M, Burke-Spolaor S, D'Amico N, Johnston S, Keith MJ, Kramer M, Kulkarni SR, Levin L, Lyne AG, Milia S, Possenti A, Spitler L, Stappers B, van Straten W.

Science. 2011 Sep 23;333(6050):1717-20. doi: 10.1126/science.1208890. Epub 2011 Aug 25.

13.

Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.

Spitler LE, Weber RW, Allen RE, Meyer J, Cruickshank S, Garbe E, Lin HY, Soong SJ.

J Immunother. 2009 Jul-Aug;32(6):632-7. doi: 10.1097/CJI.0b013e3181a7d60d.

PMID:
19483646
14.

A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma.

Lutzky J, Weber R, Nunez Y, Gillett M, Spitler L.

J Immunother. 2009 Jan;32(1):79-85. doi: 10.1097/CJI.0b013e31818c8aaf.

PMID:
19307996
15.

Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.

Weber RW, O'Day S, Rose M, Deck R, Ames P, Good J, Meyer J, Allen R, Trautvetter S, Timmerman M, Cruickshank S, Cook M, Gonzalez R, Spitler LE.

J Clin Oncol. 2005 Dec 10;23(35):8992-9000. Epub 2005 Oct 31.

PMID:
16260693
16.

Noninterferon-based adjuvant therapy for high-risk melanoma.

Spitler LE.

Expert Rev Anticancer Ther. 2002 Oct;2(5):547-62. Review.

PMID:
12382523
17.
18.

Recovery of zeta-chain expression and changes in spontaneous IL-10 production after PSA-based vaccines in patients with prostate cancer.

Meidenbauer N, Gooding W, Spitler L, Harris D, Whiteside TL.

Br J Cancer. 2002 Jan 21;86(2):168-78.

19.

Adjuvant therapy of melanoma.

Spitler LE.

Oncology (Williston Park). 2002 Jan;16(1 Suppl 1):40-8. Review.

20.

Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma.

Dillman RO, DeLeon C, Beutel LD, Barth NM, Schwartzberg LS, Spitler LE, Garfield DH, O'Connor AA, Nayak SK.

Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):115-23.

PMID:
11418308
21.

Adjuvant therapy of melanoma: at what cost?

Spitler LE.

J Clin Oncol. 2001 Feb 15;19(4):1226-8. No abstract available.

PMID:
11181688
22.

Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer.

Meidenbauer N, Harris DT, Spitler LE, Whiteside TL.

Prostate. 2000 May 1;43(2):88-100.

PMID:
10754524
23.

Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma.

Dillman RO, Nayak SK, Barth NM, DeLeon C, Schwartzberg LS, Spitler LE, Church C, O'Connor AA, Beutel LD.

Cancer Biother Radiopharm. 1998 Jun;13(3):165-76.

PMID:
10850352
24.

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor.

Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA, Soong SJ.

J Clin Oncol. 2000 Apr;18(8):1614-21.

PMID:
10764421
25.

Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery.

Muderhwa JM, Matyas GR, Spitler LE, Alving CR.

J Pharm Sci. 1999 Dec;88(12):1332-9.

PMID:
10585231
26.

Immunologic approaches to the treatment of prostate cancer.

Harris DT, Matyas GR, Gomella LG, Talor E, Winship MD, Spitler LE, Mastrangelo MJ.

Semin Oncol. 1999 Aug;26(4):439-47. Review.

PMID:
10482186
27.

Cancer vaccines: the interferon analogy.

Spitler LE.

Cancer Biother. 1995 Spring;10(1):1-3. No abstract available.

PMID:
7540087
28.

Penetration of anti-melanoma immunotoxin into multicellular tumor spheroids and cell kill effects.

Kikuchi T, Ohnuma T, Holland JF, Spitler LE.

Cancer Immunol Immunother. 1992;35(5):302-6.

PMID:
1394334
29.

Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial.

Gonzalez R, Salem P, Bunn PA Jr, Zukiwski AA, Lamb R, Benjamin RS, Spitler L, Wedel N, Robinson WA.

Mol Biother. 1991 Dec;3(4):192-6.

PMID:
1768370
30.

Continuous infusion interleukin-2 and tumor-derived activated cells as treatment of advanced solid tumors: a National Biotherapy Study Group Trial.

Oldham RK, Dillman RO, Yannelli JR, Barth NM, Maleckar JR, Sferruzza A, Cohen RJ, Minor DR, Spitler L, Birch R, et al.

Mol Biother. 1991 Jun;3(2):68-73.

PMID:
1910622
31.
32.

The effects of cyclophosphamide on the toxicity and immunogenicity of ricin A chain immunotoxin in rats.

Stoudemire JB, Mischak R, Foxall C, Harkonen WS, Del Rio M, Spitler LE.

Mol Biother. 1990 Sep;2(3):179-84.

PMID:
2222902
33.

Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial.

Oratz R, Speyer JL, Wernz JC, Hochster H, Meyers M, Mischak R, Spitler LE.

J Biol Response Mod. 1990 Aug;9(4):345-54.

PMID:
2395000
34.

Human antibody responses to components of the monoclonal antimelanoma antibody ricin A chain immunotoxin XomaZyme-MEL.

Mischak RP, Foxall C, Rosendorf LL, Knebel K, Scannon PJ, Spitler LE.

Mol Biother. 1990 Jun;2(2):104-9.

PMID:
2363853
35.

Monoclonal antibodies in the treatment of malignant melanoma.

Spitler LE.

Front Radiat Ther Oncol. 1990;24:186-93; discussion 202-3. No abstract available.

PMID:
2140337
36.

Therapy of metastatic malignant melanoma using Xomazyme Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin.

Spitler LE, Mischak R, Scannon P.

Int J Rad Appl Instrum B. 1989;16(6):625-7. No abstract available.

PMID:
2606718
37.

Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients.

Harkonen S, Scannon P, Mischak RP, Spitler LE, Foxall C, Kennedy D, Greenberg R.

Antimicrob Agents Chemother. 1988 May;32(5):710-6.

38.

A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma.

Miller LL, Spitler LE, Allen RE, Minor DR.

Cancer. 1988 Apr 15;61(8):1543-9.

PMID:
3280114
39.

Clinical studies: solid tumors.

Spitler LE.

Cancer Treat Res. 1988;37:493-514. No abstract available.

PMID:
2908641
40.

Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin.

Spitler LE, del Rio M, Khentigan A, Wedel NI, Brophy NA, Miller LL, Harkonen WS, Rosendorf LL, Lee HM, Mischak RP, et al.

Cancer Res. 1987 Mar 15;47(6):1717-23.

41.

Toxicity and immunogenicity of monoclonal antimelanoma antibody-ricin A chain immunotoxin in rats.

Harkonen S, Stoudemire J, Mischak R, Spitler LE, Lopez H, Scannon P.

Cancer Res. 1987 Mar 1;47(5):1377-82.

42.

Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma.

Hertler AA, Spitler LE, Frankel AE.

Cancer Drug Deliv. 1987;4(4):245-53.

PMID:
3502618
43.

Clinical trials of transfer factor in malignancy.

Spitler LE, Miller L.

J Exp Pathol. 1987 Summer;3(4):549-64. Review.

PMID:
3331650
44.

Improved immune-specificity in monoclonal radioimmunoimaging using dual radionuclide color functional maps.

Engelstad BL, Ramos EC, Stoudemire J, O'Connell JW, Villanueva J, Faulkner DB, Hattner RS, Spitler LE, Scannon P.

Invest Radiol. 1986 Dec;21(12):917-21.

PMID:
3804658
45.

Phase 1 immunolymphoscintigraphy with an In-111-labeled antimelanoma monoclonal antibody.

Engelstad BL, Spitler LE, Del Rio MJ, Ramos EC, Rosendorf LL, Reinhold CE, Khentigan A, Huberty JP, Corpuz SW, Lee HM, et al.

Radiology. 1986 Nov;161(2):419-22.

PMID:
3763912
46.

Immunotoxin therapy of malignant melanoma.

Spitler LE.

Med Oncol Tumor Pharmacother. 1986;3(3-4):147-52. Review.

PMID:
3543527
47.
49.

Experimental allergic encephalitis; treatment with drugs which alter CNS serotonin levels.

Scott CF Jr, Cashman N, Spitler LE.

J Immunopharmacol. 1982-1983;4(3):153-62.

PMID:
7184959
50.

Serum copper and zinc levels in melanoma patients.

Fisher GL, Spitler LE, McNeill KL, Rosenblatt LS.

Cancer. 1981 Apr 1;47(7):1838-44.

PMID:
7226078

Supplemental Content

Loading ...
Support Center